PDA
Pentadeca Arginate / BPC-157 arginate salt
PDA (Pentadeca Arginate / BPC-157 arginate salt) is a healing & recovery research compound. The BPC-157 pentadecapeptide supplied as an arginate salt rather than the usual acetate. The sequence, and therefore the mechanism, is the same: VEGFR2 and nitric-oxide signalling driving angiogenesis, with the growth-factor upregulation behind the tendon, gut, muscle and nerve repair BPC-157 is known for. What the arginate counter-ion changes is the physical chemistry of the salt, and vendors market it as the more stable of the two. That is a formulation claim, not a potency claim: nobody has published a head-to-head of arginate against acetate in a living system.
PDA quick facts
| Route | Subq |
| Frequency | 1-2x Daily Am and PM · 5 On 2 Off or Daily |
| Half-life | ~4 hrs systemic, longer locally, as BPC-157 |
| Forms | Injectable |
| Evidence level | Same peptide as BPC-157 - strong animal, heavy anecdotal, limited human. The arginate salt specifically has no comparative data at all. |
Run it as you would BPC-157 - same sequence, same mechanism. The dose shown is carried over from BPC-157 rather than read off a PDA label, because no vendor publishes one. If you already have BPC-157 that works for you, the arginate salt is a stability and shelf-life argument, not a stronger molecule; treat any claim that it is more potent as marketing until someone runs the comparison.
How PDA works
The BPC-157 pentadecapeptide supplied as an arginate salt rather than the usual acetate. The sequence, and therefore the mechanism, is the same: VEGFR2 and nitric-oxide signalling driving angiogenesis, with the growth-factor upregulation behind the tendon, gut, muscle and nerve repair BPC-157 is known for. What the arginate counter-ion changes is the physical chemistry of the salt, and vendors market it as the more stable of the two. That is a formulation claim, not a potency claim: nobody has published a head-to-head of arginate against acetate in a living system.
Proposed benefits
Tendon, gut and soft-tissue repair — the BPC-157 peptide as an arginate salt, sold on shelf stability rather than a different mechanism.
✅ Clinically validated
- No human trial of PDA exists, and none of BPC-157 either. PDA is the same pentadecapeptide supplied as an arginate salt, so it inherits BPC-157's evidence position exactly: strong animal work, no completed randomised human efficacy trial, and a 2023 FDA move to bulk-substances category 2 that restricts compounding — a judgement about missing data, not a finding of harm.
- Nothing compares the two salts in a living system. The arginate is marketed as more stable. Stability is a property of the powder in the vial; it is not a claim about what happens after injection, and no published work bridges the two.
📊 Correlative data
- The anecdotal record people cite for PDA is BPC-157's record, because the peptide is the same. That record is large and it is also the clearest case in the Vault of anecdote being a weak instrument: soft-tissue injuries and gut flares resolve on their own, so anything taken during recovery collects the credit.
- PDA's own anecdotal history is short — it entered the research market recently, and reports specific to the arginate salt are too few and too new to separate from BPC-157's.
🧪 Theoretical / extrapolated
- Identical to BPC-157 by definition: VEGFR2 and nitric-oxide signalling driving angiogenesis, with growth-factor upregulation behind tendon, gut, muscle and nerve repair. A counter-ion changes the salt's physical chemistry, not the peptide's sequence or its receptor interactions.
- The mechanistic argument FOR the arginate is pharmacokinetic — a more stable salt could mean more intact peptide surviving to the point of action. Plausible, unmeasured, and worth treating as a hypothesis rather than a feature.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Where to get PDA
Buy PDA at Ion Peptide →PDA — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What PDA moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for PDA — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
Get the complete breakdown for PDA — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside PDA
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anaemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 102 markers A–Z
PDA — frequently asked questions
What is PDA?
PDA (Pentadeca Arginate / BPC-157 arginate salt) is a healing & recovery research compound. The BPC-157 pentadecapeptide supplied as an arginate salt rather than the usual acetate. The sequence, and therefore the mechanism, is the same: VEGFR2 and nitric-oxide signalling driving angiogenesis, with the growth-factor upregulation behind the tendon, gut, muscle and nerve repair BPC-157 is known for. What the arginate counter-ion changes is the physical chemistry of the salt, and vendors market it as the more stable of the two. That is a formulation claim, not a potency claim: nobody has published a head-to-head of arginate against acetate in a living system.
Where can I find PDA dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full PDA protocol are available to members inside the Academy. This public page covers what PDA is, how it works and the evidence.
What is the half-life of PDA?
PDA has an approximate half-life of ~4 hrs systemic, longer locally, as BPC-157, which is part of what determines how often it's dosed.
What's the evidence behind PDA?
Current evidence level: Same peptide as BPC-157 - strong animal, heavy anecdotal, limited human. The arginate salt specifically has no comparative data at all.. PDA is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact PDA protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →